JP2018500365A - 治療方法 - Google Patents

治療方法 Download PDF

Info

Publication number
JP2018500365A
JP2018500365A JP2017534610A JP2017534610A JP2018500365A JP 2018500365 A JP2018500365 A JP 2018500365A JP 2017534610 A JP2017534610 A JP 2017534610A JP 2017534610 A JP2017534610 A JP 2017534610A JP 2018500365 A JP2018500365 A JP 2018500365A
Authority
JP
Japan
Prior art keywords
formula
compound
coating
formulation
core
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
JP2017534610A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018500365A5 (cg-RX-API-DMAC7.html
Inventor
ケイ,デビッド
Original Assignee
カーディオラ ピーティーワイ リミテッド
カーディオラ ピーティーワイ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014905194A external-priority patent/AU2014905194A0/en
Application filed by カーディオラ ピーティーワイ リミテッド, カーディオラ ピーティーワイ リミテッド filed Critical カーディオラ ピーティーワイ リミテッド
Publication of JP2018500365A publication Critical patent/JP2018500365A/ja
Publication of JP2018500365A5 publication Critical patent/JP2018500365A5/ja
Priority to JP2021210184A priority Critical patent/JP7475324B2/ja
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2017534610A 2014-12-22 2015-12-21 治療方法 Revoked JP2018500365A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021210184A JP7475324B2 (ja) 2014-12-22 2021-12-24 治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014905194A AU2014905194A0 (en) 2014-12-22 Method of Treatment
AU2014905194 2014-12-22
PCT/AU2015/050820 WO2016101024A1 (en) 2014-12-22 2015-12-21 Method of treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021210184A Division JP7475324B2 (ja) 2014-12-22 2021-12-24 治療方法

Publications (2)

Publication Number Publication Date
JP2018500365A true JP2018500365A (ja) 2018-01-11
JP2018500365A5 JP2018500365A5 (cg-RX-API-DMAC7.html) 2019-02-07

Family

ID=56148784

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017534610A Revoked JP2018500365A (ja) 2014-12-22 2015-12-21 治療方法
JP2021210184A Active JP7475324B2 (ja) 2014-12-22 2021-12-24 治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021210184A Active JP7475324B2 (ja) 2014-12-22 2021-12-24 治療方法

Country Status (12)

Country Link
US (2) US10493067B2 (cg-RX-API-DMAC7.html)
EP (1) EP3236963B1 (cg-RX-API-DMAC7.html)
JP (2) JP2018500365A (cg-RX-API-DMAC7.html)
KR (1) KR20170098897A (cg-RX-API-DMAC7.html)
CN (1) CN107530337B (cg-RX-API-DMAC7.html)
AU (1) AU2015372434B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017013015A2 (cg-RX-API-DMAC7.html)
EA (1) EA201791455A1 (cg-RX-API-DMAC7.html)
IL (1) IL253028B (cg-RX-API-DMAC7.html)
MX (1) MX2017008248A (cg-RX-API-DMAC7.html)
SG (1) SG11201704980XA (cg-RX-API-DMAC7.html)
WO (1) WO2016101024A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017013015A2 (pt) * 2014-12-22 2018-03-06 Cardiora Pty Ltd método de tratamento de um paciente que possui falência cardíaca com fração de ejeção preservada (hfpef)
US11969422B2 (en) 2020-12-10 2024-04-30 Imbria Pharmaceuticals, Inc. Methods of treating heart failure with reduced ejection fraction using modified forms of trimetazidine
US11730733B2 (en) 2020-12-10 2023-08-22 Imbria Pharmaceuticals, Inc. Methods of treating non-obstructive hypertrophic cardiomyopathy using modified forms of trimetazidine
US11793807B2 (en) 2020-12-10 2023-10-24 Imbria Pharmaceuticals, Inc. Methods of treating heart failure with preserved ejection fraction using modified forms of trimetazidine
US12076318B2 (en) 2020-12-10 2024-09-03 Imbria Pharmaceuticals, Inc. Methods of treating heart failure with hibernating myocardium using modified forms of trimetazidine
EP4259138A4 (en) * 2020-12-10 2024-11-06 Imbria Pharmaceuticals, Inc. METHODS OF TREATING CARDIAC DISORDERS USING MODIFIED FORMS OF TRIMETAZIDINE

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014521727A (ja) * 2011-08-16 2014-08-28 ベイカー アイディーアイ ハート アンド ダイアベーツ インスティテュート ホールディングス リミテッド 制御放出製剤

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4297360A (en) 1980-03-28 1981-10-27 Sterling Drug Inc. 5-(Pyridinyl)pyridine-2,3-diamines, preparation thereof and their cardiotonic use
NZ195564A (en) 1979-11-26 1983-09-30 Sterling Drug Inc 5-pyridinyl-2(1h)-pyridinones pharmaceutical compositions intermediate pyridine compounds
US4313951A (en) 1979-11-26 1982-02-02 Sterling Drug Inc. 3-Substituted-6-(lower-alkyl)-5-(pyridinyl)-2(1H)-pyridinones, their cardiotonic use and intermediates therefor
GB8414220D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Medicaments in unit dose form
US4786503A (en) 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5009895A (en) 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
US5213811A (en) 1991-09-13 1993-05-25 Sterling Drug Inc. Oral sustained-release drug compositions
SK279684B6 (sk) 1993-06-14 1999-02-11 Janssen Pharmaceutica N.V. Tableta a spôsob jej výroby
US5662933A (en) 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
GB9402203D0 (en) 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
AU2003261298A1 (en) 2002-08-02 2004-02-23 Penwest Pharmaceuticals Company Sustained release formulations of metformin
KR100548925B1 (ko) 2002-10-23 2006-02-02 한미약품 주식회사 약물의 경구투여용 서방성 조성물
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
JP5547865B2 (ja) 2003-10-29 2014-07-16 ワイス・エルエルシー アプリンドルおよびその誘導体を含む持続放出型医薬組成物
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
WO2010133815A1 (en) 2009-05-20 2010-11-25 Heart Metabolics Limited Treatment of heart failure with normal ejection fraction
CN103608662B (zh) * 2011-06-29 2016-09-28 京都府公立大学法人 肿瘤部位的识别装置以及识别方法
CA2861804C (en) 2011-12-27 2021-10-26 Ironwood Pharmaceuticals, Inc. 2-benzyl,3(pyrimidin-2-yl)substituted pyrazoles useful as sgc stimulators
WO2013116194A2 (en) * 2012-01-30 2013-08-08 O'connell Timothy D Method of treating or limiting development of heart failure with preserved ejection fraction and tissue fibrosis
BR112017013015A2 (pt) * 2014-12-22 2018-03-06 Cardiora Pty Ltd método de tratamento de um paciente que possui falência cardíaca com fração de ejeção preservada (hfpef)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014521727A (ja) * 2011-08-16 2014-08-28 ベイカー アイディーアイ ハート アンド ダイアベーツ インスティテュート ホールディングス リミテッド 制御放出製剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHINESE JOURNAL OF CURRENT CLINICAL MEDICINE, vol. 9, no. 3, JPN6019037421, 2011, pages 148 - 150, ISSN: 0004577003 *
HEART FAILURE CLIN., vol. Vol.10, Issue 3, JPN6020036240, July 2014 (2014-07-01), pages 407 - 418, ISSN: 0004577004 *
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 62, no. 16, JPN6021032808, 2013, pages 147 - 239, ISSN: 0004577005 *
循環器病の診断と治療に関するガイドライン(2010年度合同研究班報告) 急性心不全治療ガイドライン(2011, JPN6021032809, 20 September 2013 (2013-09-20), pages 1 - 81, ISSN: 0004577006 *

Also Published As

Publication number Publication date
EP3236963A1 (en) 2017-11-01
US20170348292A1 (en) 2017-12-07
US10493067B2 (en) 2019-12-03
JP7475324B2 (ja) 2024-04-26
JP2022163681A (ja) 2022-10-26
KR20170098897A (ko) 2017-08-30
US20200101053A1 (en) 2020-04-02
BR112017013015A2 (pt) 2018-03-06
SG11201704980XA (en) 2017-07-28
NZ732954A (en) 2021-11-26
EP3236963A4 (en) 2018-08-08
WO2016101024A1 (en) 2016-06-30
IL253028B (en) 2019-12-31
US11291660B2 (en) 2022-04-05
EA201791455A1 (ru) 2017-12-29
AU2015372434A1 (en) 2017-07-13
AU2015372434B2 (en) 2018-10-04
CA2971071A1 (en) 2016-06-30
CN107530337B (zh) 2021-07-09
EP3236963B1 (en) 2020-01-29
CN107530337A (zh) 2018-01-02
IL253028A0 (en) 2017-08-31
MX2017008248A (es) 2018-02-19

Similar Documents

Publication Publication Date Title
JP7475324B2 (ja) 治療方法
JP5634882B2 (ja) 弱塩基性薬物と有機酸とを含む薬物送達システム
US11331274B2 (en) Milrinone controlled-release formulation
US20040052844A1 (en) Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
JPWO2008129846A1 (ja) 医薬組成物
EP1820506B1 (en) Dipyridamole extended-release formulations and process for preparing same
CA2971071C (en) Use of milrinone and derivatives thereof in the treatment of heart failure with preserved ejection fraction (hfpef)
NZ732954B2 (en) Method of Treating Heart Failure with Preserved Ejection Fraction with 5-(Pyridinyl)-2(1H)-pyridinone Compounds
HK1104791B (en) Dipyridamole extended-release formulations and process for preparing same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181219

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191008

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200409

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200925

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210326

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210824

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20211001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211001

AA91 Notification that invitation to amend document was cancelled

Free format text: JAPANESE INTERMEDIATE CODE: A971091

Effective date: 20220823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220826